Corcept Therapeutics Initiates Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
“Metastatic pancreatic cancer is an aggressive disease and there is an urgent need for effective therapies,” said
RELIANT has a planned enrollment of 80 patients with metastatic pancreatic cancer, with an interim analysis of data from the first 40 patients. Each patient will receive relacorilant plus nab-paclitaxel. The primary endpoint is objective response rate. Secondary endpoints include progression-free survival and duration of response. RELIANT will be conducted at 20 sites in
About Relacorilant
Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor that does not bind to the body's other hormone receptors. Corcept is studying relacorilant in a variety of serious disorders, including Cushing’s syndrome and adrenal, ovarian and pancreatic cancer. Relacorilant is proprietary to Corcept and is protected by composition of matter and method of use patents. Relacorilant has received orphan drug designation in
About
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol. Korlym® was the first drug approved by the
Abraxane® is a registered trademark of
CONTACT:
Director, Investor Relations
650-684-8725
cjames@corcept.com
www.corcept.com
1 See our ASCO poster at the Investors/Past Events tab of our website.
2 See Clinicaltrials.gov (trial identifier: NCT04329949)
Source: Corcept Therapeutics Incorporated